Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06556433 · ClinicalTrials.gov registry record · NA
Family-Based Financial Incentives Intervention for Smoking Cessation
A NA study of Smoking Cessation, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 1,312
- Enrollment target
- 1
- Study location
NCT06556433: Recruiting NA study of Smoking Cessation, sponsored by Mayo Clinic.
NCT06556433 is a NA study of Smoking Cessation that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 1,312 participants, above the 468-participant average among 188 other Smoking Cessation trials with a reported enrollment target (180% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06556433, a NA study of Smoking Cessation, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,312 participants
- Enrollment target
- 1
- Study location
Study Summary
The current study will conduct an RCT to evaluate the effectiveness of a family-based incentive intervention with Alaska Native/American Indian families. The experimental arm will be compared to a control arm on biochemically-confirmed smoking abstinence at 6- and 12-months post-intervention.
Primary Outcome
Number of participants to have biochemically verified, prolonged smoking abstinence.
Conditions Studied
Interventions
- BEHAVIORAL Financial Incentive Rewards
Study Locations (1)
Alaska
- Alaska Native Tribal Health Consortium - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,312 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2028-04-30 |
| Phase | NA |
What NCT06556433 shows while recruiting
NCT06556433 is an interventional study that assigns participants to a tested intervention. Its 1,312 participants enrollment target places it among the larger protocols in the corpus, above the 468-participant average among 188 other Smoking Cessation trials with a reported enrollment target (180% higher).
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which Financial Incentive Rewards is the first listed.
NCT06556433 reports a single indexed study location in Alaska.
Frequently Asked Questions
What is clinical trial NCT06556433 about?
NCT06556433 is a clinical study titled "Family-Based Financial Incentives Intervention for Smoking Cessation". The current study will conduct an RCT to evaluate the effectiveness of a family-based incentive intervention with Alaska Native/American Indian families. The experimental arm will be compared to a control arm on biochemically-confirmed smoking abstinence at 6- and 12-months post-intervention.
What is the current status of trial NCT06556433?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,312 participants. The study started on 2024-09-03. Estimated completion is 2028-04-30.
What conditions does trial NCT06556433 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT06556433?
The interventions under investigation include: Financial Incentive Rewards (BEHAVIORAL).
Who is sponsoring clinical trial NCT06556433?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06556433 being conducted?
This trial has 1 study location across Alaska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06556433's enrollment target sits among peer trials
1,312 15th of 188 higher than 174 of 188 other Smoking Cessation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoking Cessation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Research Evaluating Smoking Cessation With E-Cigarettes and Nicotine Therapy
RECRUITING · NA
-
Scalable TELeheaLth Cancer CARe: The STELLAR Program to Treat Cancer Risk Behaviors
RECRUITING · NA
-
ACT Lung Health Intervention: Phase Two
RECRUITING · NA
-
Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network
RECRUITING · NA
-
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
RECRUITING · NA
-
Urban and Reservation Implementation of All Nations Breath of Life
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05176483 · 1,314 participants · Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- NCT06136650 · 1,314 participants · Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- NCT06136624 · 1,310 participants · Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- NCT05762302 · 1,316 participants · NA
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI